Table 3.
Prevalence of the study outcomes across glycemic categories stratified by estimated 10-year ASCVD risk strata.
| Euglycemia | Prediabetes | Diabetes | |
|---|---|---|---|
|
| |||
| Participants with estimated risk <5% | |||
| Number | 1,143 | 428 | 41 |
| Any plaque | 387(33.9%) | 197(46.0%) | 19(46.3%) |
| Any non-calcified plaque | 260(22.7%) | 155(36.2%) | 16(39.0%) |
| Any plaque with ≥1 high-risk feature | 39(3.4%) | 24(5.6%) | 2(4.9%) |
| Stenosis ≥ 50% | 25(2.2%) | 10(2.3%) | 4(9.8%) |
| Stenosis ≥ 70% | 9(0.8%) | 3(0.7%) | 1(2.4%) |
| Participants with estimated risk ≥5 to <7.5% | |||
| Number | 171 | 133 | 24 |
| Any plaque | 117(68.4%) | 97(72.9%) | 12(50.0%) |
| Any non-calcified plaque | 86(50.3%) | 67(50.4%) | 10(41.7%) |
| Any plaque with ≥1 high-risk feature | 17(9.9%) | 16(12.0%) | 1(4.2%) |
| Stenosis ≥ 50% | 15(8.8%) | 14(10.5%) | 4(16.7%) |
| Stenosis ≥ 70% | 1(0.6%) | 6(4.5%) | 1(4.2%) |
| Participants with estimated risk ≥7.5% to <20% | |||
| Number | 152 | 135 | 77 |
| Any plaque | 114(75.0%) | 108(80.0%) | 61(79.2%) |
| Any non-calcified plaque | 86(56.6%) | 88(65.2%) | 51(66.2%) |
| Any plaque with ≥1 high-risk feature | 13(8.6%) | 25(18.5%) | 14(18.2%) |
| Stenosis ≥ 50% | 20(13.2%) | 23(17.0%) | 15(19.5%) |
| Stenosis ≥ 70% | 6(3.9%) | 9(6.7%) | 2(2.6%) |
| Participants with estimated risk ≥20% | |||
| Number | 5 | 5 | 21 |
| Any plaque | 5(100%) | 4(80.0%) | 20(95.2%) |
| Any non-calcified plaque | 5(100%) | 3(60.0%) | 14(66.7%) |
| Any plaque with ≥1 high-risk feature | 2(40.0%) | 1(20.0%) | 7(33.3%) |
| Stenosis ≥ 50% | 0(0%) | 2(40.0%) | 6(28.6%) |
| Stenosis ≥ 70% | 0(0%) | 2(40.0%) | 3(14.3%) |
ASCVD risk was estimated using the Pooled Cohort Equations.12 Results are presented as number (column %).
Abbreviation: ASCVD, atherosclerotic cardiovascular disease.
Note: Total cholesterol values were missing for 17 participants, for whom ASCVD risk was not calculated.